



IMPROVING ACCESS TO CANCER THERAPEUTICS THROUGH STAKEHOLDERS ENGAGEMENT: 2-YEARS' EXPERIENCE IN THE LARGEST PRIVATE HEALTHCARE PROVIDER IN ONCOLOGY IN BRAZIL

OP10

Sales R, Silva BC, Oliveira DM, Laloní MT, Ferreira CG, Andrade Filho LE, Ferrari B, Aguiar Jr PN
Oncoclínicas&Co/MedSir, Belo Horizonte, MG, Brazil, Oncoclínicas&Co/MedSir, São Paulo, SP, Brazil
rahyssa.sales@oncoclinicas.com

OBJECTIVES

The rapid development and increasing cost of new cancer drugs may lead to several barriers to patient access. In the largest Oncology Network in Brazil, a Medical Access Support Program has been implemented in line with the ISPOR Top 10 HEOR. We aimed to evaluate the outcomes of the program after two years of experience.

METHODS




Fig. 1: Flowchart of the Medical Access Support (MAS) program.

RESULTS




Fig. 2: Funnel diagram of the cases referred to the MAS program.

CONCLUSIONS

- The MAS Program showed promising results over a two-years period and is establishing itself as a key strategy for the company.
- Notable achievements include rapid and equitable access to treatment for more than half of the patients, despite regulatory barriers to access.
- It promotes system sustainability and reduces litigation.
- Additionally, its role as an interface between the clinical team and stakeholders enables more accurate decision making, adding value to healthcare.
- Continued evaluation is recommended to explore its potential in different contexts and to assess its long-term impacts in terms of patients survival outcomes.

